Apnimed
The combination drug composed of aroxybutynin and atomoxetine, designated AD109, is being developed by Apnimed for the treatment of obstructive sleep apnea (OSA). The present study is a Phase 3 open label continuation protocol enrolling qualifying participants who completed one of the parent Phase 3 double-blind placebo-controlled studies, APC-APN-304 or APC-APN-305.
OSA
Aroxybutynin and Atomoxetine
PHASE3
Study Type : | INTERVENTIONAL |
Estimated Enrollment : | 1280 participants |
Masking : | NONE |
Primary Purpose : | OTHER |
Official Title : | A Phase 3 Open Label Continuation Protocol of a Fixed Dose Combination of Aroxybutynin and Atomoxetine (AD109) in Obstructive Sleep Apnea |
Actual Study Start Date : | 2024-07-03 |
Estimated Primary Completion Date : | 2026-06-30 |
Estimated Study Completion Date : | 2026-06-30 |
Information not available for Arms and Intervention/treatment
Ages Eligible for Study: | 18 Years |
Sexes Eligible for Study: | ALL |
Accepts Healthy Volunteers: | 1 |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
RECRUITING
Core Healthcare Group
Cerritos, California, United States, 90703
RECRUITING
Exalt Clinical Research, Inc.
Chula Vista, California, United States, 91910
RECRUITING
Canvas Clinical Research
Lake Worth, Florida, United States, 33467
RECRUITING
Clinical Neuroscience Solutions, Inc.
Orlando, Florida, United States, 32801
RECRUITING
Georgia Neurology and Sleep Medicine Associates
Suwanee, Georgia, United States, 30024
RECRUITING
Centennial Medical Group Research Department
Columbia, Maryland, United States, 21045
RECRUITING
Abington Neurological Associates
Abington, Pennsylvania, United States, 19001
RECRUITING
FutureSearch Trials of Dallas
dallas, Texas, United States, 75231
RECRUITING
Huntsville Research Institute
Huntsville, Texas, United States, 77340